Inside CDD Vault, A Different Kind of Silicon Valley Success Story: Behind the Code: the Human Side of Collaborative Drug Discovery

Author:   Barry Bunin
Publisher:   Collaborative Drug Discovery, Inc.
ISBN:  

9798993644301


Pages:   176
Publication Date:   15 November 2025
Format:   Paperback
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Our Price $65.97 Quantity:  
Add to Cart

Share |

Inside CDD Vault, A Different Kind of Silicon Valley Success Story: Behind the Code: the Human Side of Collaborative Drug Discovery


Overview

Inside CDD Vault takes readers into a different kind of Silicon Valley story--one balancing long-term growth with a mission catalyzing scientific progress for the greater good. Go deep into the hearts of the people helping scientists discover new medicines. Told through the personal journeys of team members--from executives to engineers to scientists--this book reveals the human stories behind the software, the values that shape the company's unusual path. From the emotional weight of personal loss to the practical triumphs of global collaboration, Inside CDD Vault is a story of trauma, resilience, and meaning. It's about building a business that's both for-profit and for-purpose.

Full Product Details

Author:   Barry Bunin
Publisher:   Collaborative Drug Discovery, Inc.
Imprint:   Collaborative Drug Discovery, Inc.
Dimensions:   Width: 15.20cm , Height: 1.20cm , Length: 22.90cm
Weight:   0.336kg
ISBN:  

9798993644301


Pages:   176
Publication Date:   15 November 2025
Audience:   General/trade ,  General
Format:   Paperback
Publisher's Status:   Active
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Table of Contents

Reviews

Author Information

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $100 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis¿ (Carfilzomib for Injection) - a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen's $10.4 Billion acquisition of Onyx Pharmaceuticals.Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored ""Chemoinformatics: Theory, Practice, and Products"" (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and ""The Combinatorial Index"" (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

NOV RG 20252

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List